276702-25-1

Upstream product

• 761448-09-3 2-(tert-butyl)-6-chloro-N,N-dimethylbenzo[d]oxazole-7-sulfonamide 
• 361392-60-1 2-tert-butyl-6-chloro-benzooxazole-7-sulfonyl chloride 
• 276702-24-0 N,N-dimethyl-6-chloro-2-hydroxy-3-nitrobenzenesulfonamide 

Downstream Products

• 364363-36-0 N-[4-chloro-2-hydroxy-3-(N,N-dimethylaminosulfonyl)phenyl]-N'-(2-trifluoromethylphenyl) thiourea 
• 361393-21-7 N-[4-chloro-2-hydroxy-3-(N'',N''-dimethylaminosulfonyl)phenyl]-N'-(2-bromophenyl)-thiourea 
• 914638-58-7 6-chloro-3-[3-(2-ethyl-phenyl)-thioureido]-2-hydroxy-N,N-dimethyl-benzenesulfonamide 
• 914638-57-6 3-(3-biphenyl-2-yl-thioureido)-6-chloro-2-hydroxy-N,N-dimethyl-benzenesulfonamide 
• 364363-42-8 N-[4-chloro-2-hydroxy-3-(N,N-dimethylaminosulfonyl)phenyl]-N'-(2-fluorophenyl) thiourea 
• 364363-39-3 N-[4-Chloro-2-hydroxy-3-(N,N-dimethylaminosulfonyl)phenyl]-N'-(2-methylphenyl) thiourea 
• 17356-08-0 thiourea 
• 364363-30-4 N-[4-Chloro-2-hydroxy-3-(N,N-dimethylaminosulfonyl)phenyl]-N'-(2-chlorophenyl) thiourea 
• 361393-20-6 N-[4-chloro-2-hydroxy-3-(N'',N''-dimethylaminosulfonyl)phenyl]-N'-(2,3-dichlorophenyl)-thiourea 
• 276700-44-8 N-[4-Chloro-3-(N,N-dimethylaminosulfonyl)-2-hydroxyphenyl]-N'-(2,3-dichlorophenyl) urea 
• 1092389-22-4 6-chloro-3-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)-2-hydroxy-N,N-dimethylbenzenesulfonamide 
• 1092388-85-6 6-chloro-2-hydroxy-N,N-dimethyl-3-{2-[(R)-1-((2R,5R)-5-methyltetrahydrofuran-2-yl)propylamino]-3,4-dioxocyclobut-1-enylamino}benzenesulfonamide 
• 364363-37-1 N-(2-Trifluoromethylphenyl)-N'-[4-chloro-2-tert-butyldimethylsilyloxy-3-(N,N-dimethylaminosulfonyl)phenyl] thiourea 

Relevant academic research and scientific papers

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the tr

DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the

ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS

The present invention relates to compounds of formula (I) with the substituents as defined herein, and uses thereof.

N,N′-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors

A series of N-(2-hydroxy-3-sulfonamidobenzene)-N′-arylcyanoguanidines was prepared. In general, these compounds proved to be potent antagonists of CXCR2 while the selectivity versus CXCR1 ranged from non-selective to >200-fold.

Discovery of potent and orally bioavailable N,N′-diarylurea antagonists for the CXCR2 chemokine receptor

A series of 3-substituted N,N′-diarylureas was prepared and CXCR2 receptor affinities as well as pharmacokinetic properties were examined. A series of 3-substituted N,N′-diarylureas was prepared and the structure-activity relationship relative to CXCR2 re

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists

Novell IL-8 compounds and methods of using them are provided.